Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration with a voluntary action indicated (VAI) classification for its injectable manufacturing facility at Zydus Biotech Park in Ahmedabad.
The good manufacturing practices inspection was conducted from April 27 to May 5, according to a Saturday filing with the Indian bourses.
A VAI classification means the USFDA identified objectionable conditions or practices but does not plan to take or recommend regulatory or administrative action, according to the USFDA website.
Shares of the company fell nearly 1% in early trade on Monday.